Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HB 202

Next Previous
Drug Profile

HB 202

Alternative Names: Eseba-vec; HB-200; HB-202; HB200 programme; TheraT® PICV

Latest Information Update: 15 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hookipa Pharma
  • Class Antineoplastics; Cancer vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Head and neck cancer; Squamous cell cancer
  • Phase I/II Cancer

Most Recent Events

  • 11 Nov 2024 Updated efficacy data from a phase I/II trial in Head and neck carcinoma released by Hookipa Pharma
  • 31 Oct 2024 Hookipa Pharma completes enrollment in the phase I/II trial in Cancer (Second-line therapy or greater, Combination therapy, Monotherapy, Metastatic disease, Recurrent) in USA, Netherland and Spain (Intratumoural)
  • 30 Oct 2024 HB 202 receives Fast track status from the US FDA for Oropharyngeal squamous cell carcinoma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top